Vesnarinone

Vesnarinone is a small molecule cardiotonic agent and quinolinone derivative developed as an oral inotropic drug for the treatment of heart failure. Its mechanism of action involves mixed inhibition of phosphodiesterase 3 (PDE3) and modulation of cardiac ion channels, resulting in modest, dose-dependent positive inotropic effects with minimal negative chronotropic activity. Vesnarinone increases intracellular calcium by inhibiting PDE3, prolongs sodium channel opening time, and decreases delayed outward and inward rectifying potassium currents. It also exhibits immunomodulatory properties by suppressing cytokine production such as TNF-alpha and IFN-gamma. The drug was primarily developed to improve ventricular performance in patients with severe heart failure but has also been investigated for other indications including HIV infections and Kaposi's sarcoma; however, development for these non-cardiac indications was discontinued due to lack of efficacy or safety concerns[1][2][3][4][5][6][7].

Brand names

Arkin Z

Other names

vesnarinoneArkin-ZPiteranometozineVesnarinonaVesnarinonum